Sharps Technology (Nasdaq: STSS), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announced the signing of a distribution agreement with its partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.

Digital Ally (Nasdaq: DGLY) announced plans to complete a corporate spin-off of its newly formed division, Kustom Entertainment, in the first half of 2023. Kustom Entertainment will focus on live event and concert production to accompany TicketSmarter’s ability to offer primary and secondary ticketing options.

Inspira Technologies (Nasdaq: IINN), a groundbreaking respiratory support technology company, signed an agreement to conduct a clinical study of the HYLA blood sensor with Sheba Medical Center in Israel. The clinical study, expected to commence in the first quarter of 2023, will be performed in an operating room setting in patients undergoing open heart surgery using a cardiopulmonary bypass machine (CPB). The study objective is to further evaluate the HYLA blood sensor's capabilities to measure blood gases in a non-invasive and continuous manner. The study results are expected to have a significant contribution to the product's development.

KWESST Micro Systems (Nasdaq: KWE) announced that it has delivered the first Phantom(TM) system to General Dynamics Land Systems ("GDLS-C") as part of GDLS-C's bid for several hundred next-generation reconnaissance vehicles for the U.S. Marine Corps. The Phantom(TM) capability is designed to meet evolving Electro-Magnetic Spectrum Operations ("EMSO") tactics, techniques, and procedures to be employed by reconnaissance operators in a contested Radio Frequency ("RF") environment, a feature of the modern battlefield as seen in conflict zones like Ukraine and elsewhere.